Showing results (1091-1100 of 2,117) with videos related to
Sort By:
Pageof 212
International Clinical Psychopharmacology|December 20, 2002
Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorderNienke H Tenney, Damiaan A J P Denys, Harold J G M van Megen, et al.International Clinical Psychopharmacology|December 20, 2002
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidolToshiya Inada, Charles M Beasley, Yoko Tanaka, et al.International Clinical Psychopharmacology|December 20, 2002
Optimal dose of risperidone and olanzapine for patients with schizophrenia in TaiwanChia-Yih Liu, Nan-Ying Chiu, Ching-Kuan Wu, et al.International Clinical Psychopharmacology|April 11, 2003
Dopaminergic deficit and mood disordersLuca Pania, Gian Luigi GessabInternational Clinical Psychopharmacology|April 11, 2003
Dopaminergic deficit and the role of amisulpride in the treatment of schizophreniaSiegfried KasperInternational Clinical Psychopharmacology|April 19, 2003
The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient settingEllen B Dennehy, Kimberly Doyle, Trisha SuppesInternational Clinical Psychopharmacology|April 19, 2003
Precautionary measures reduce risk of definite neuroleptic malignant syndrome in newly typical neuroleptic-treated schizophrenia inpatientsRoni Shiloh, Avi Valevski, Liron Bodinger, et al.International Clinical Psychopharmacology|January 22, 2002
Lorazepam, sedation, and conscious recollection: a dose-response study with healthy volunteersC Huron, A Giersch, J M DanionInternational Clinical Psychopharmacology|January 22, 2002
Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group studyG B Cassano, M C Jori, International Clinical Psychopharmacology|January 22, 2002
Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorderN Mohr, B Vythilingum, R A Emsley, et al.Pageof 212